---
title: "Anthropic Documentation"
description: "Formatted documentation for Anthropic"
source: "llms-full.txt"
last_updated: "2025-11-08"
---

## How to chain prompts

1. **Identify subtasks**: Break your task into distinct, sequential steps.
2. **Structure with XML for clear handoffs**: Use XML tags to pass outputs between prompts.
3. **Have a single-task goal**: Each subtask should have a single, clear objective.
4. **Iterate**: Refine subtasks based on Claude's performance.

### Example chained workflows:

* **Multi-step analysis**: See the legal and business examples below.
* **Content creation pipelines**: Research â†’ Outline â†’ Draft â†’ Edit â†’ Format.
* **Data processing**: Extract â†’ Transform â†’ Analyze â†’ Visualize.
* **Decision-making**: Gather info â†’ List options â†’ Analyze each â†’ Recommend.
* **Verification loops**: Generate content â†’ Review â†’ Refine â†’ Re-review.

<Tip>**Optimization tip**: For tasks with independent subtasks (like analyzing multiple docs), create separate prompts and run them in parallel for speed.</Tip>

### Advanced: Self-correction chains

You can chain prompts to have Claude review its own work! This catches errors and refines outputs, especially for high-stakes tasks.

<AccordionGroup>
  <Accordion title="Example: Self-correcting research summary">
    #### Prompt 1

    | Role                         | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
    | ---------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
    | User                         | Summarize this medical research paper.<br /><br />\<paper>\{\{RESEARCH\_PAPER}}\</paper><br /><br />Focus on methodology, findings, and clinical implications.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
    | Assistant<br />\{\{SUMMARY}} | Methodology: Double-blind RCT with 500 Type 2 diabetes patients. Group A (n=250) received novel GLP-1/GIP dual agonist; Group B (n=250) received standard GLP-1 agonist. 24-week trial, primary endpoint: HbA1c reduction.<br /><br />Findings:<br />- Group A: 1.8% mean HbA1c reduction<br />- Group B: 1.1% mean HbA1c reduction<br />- 68% of Group A vs. 52% of Group B achieved HbA1c \<7%<br />- Group A: 5.2kg mean weight loss<br />- Group B: 3.1kg mean weight loss<br /><br />Safety: Similar adverse event profiles, no serious events attributed to treatment.<br /><br />Clinical Implications: Dual agonist shows superior glycemic control and weight loss compared to standard therapy. Could be a game-changer, especially for obese diabetics. |

    #### Prompt 2

    | Role                          | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
    | ----------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
    | User                          | Your task is to provide feedback on a research paper summary. Here is a summary of a medical research paper:<br />\<summary><br />\{\{SUMMARY}}<br />\</summary><br /><br />Here is the research paper:<br />\<paper><br />\{\{RESEARCH\_PAPER}}<br />\</paper><br /><br />Review this summary for accuracy, clarity, and completeness on a graded A-F scale.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
    | Assistant<br />\{\{FEEDBACK}} | 1. Accuracy: A<br />   - Correctly reported key stats: HbA1c reductions, weight loss.<br />   - Accurately noted safety profile and lack of serious adverse events.<br />   - Assertion of "game-changer" is justified by significantly better outcomes.<br /><br />2. Clarity: A-<br />   - Concise and well-structured with clear sections.<br />   - Good use of comparative language (e.g., "up 3% from Q1") for context.<br />   - Minor issue: Acronyms like "RCT," "GLP-1," and "GIP" not defined. Consider spelling out first use.<br /><br />3. Completeness: B+<br />   - Covers all requested areas: methodology, findings, clinical implications.<br />   - Missing: Baseline characteristics of groups (were they well-matched?).<br />   - Missing: Any secondary endpoints (e.g., blood pressure, lipids).<br />   - Consider: Long-term implications or need for further research.<br /><br />Overall, the summary is accurate and clear, providing key insights for a quick grasp of the study. To elevate to A+, define acronyms, mention group baseline stats, note any secondary outcomes, and briefly touch on the need for long-term studies. |

    #### Prompt 3

    | Role      | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
    | --------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
    | User      | Your task is to improve a paper summary given feedback. Here is the first draft of a medical research paper:<br />\<summary><br />\{\{SUMMARY}}<br />\</summary><br /><br />Here is the research paper:<br />\<paper><br />\{\{RESEARCH\_PAPER}}<br />\</paper><br /><br />Here is the feedback:<br />\<feedback><br />\{\{FEEDBACK}}<br />\</feedback><br /><br />Update the summary based on the feedback.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
    | Assistant | Methodology: Double-blind randomized controlled trial (RCT) with 500 Type 2 diabetes patients. Group A (n=250) received a novel glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) dual agonist; Group B (n=250) received a standard GLP-1 agonist. The 24-week trial's primary endpoint was HbA1c reduction. Groups were well-matched for age, BMI, and baseline HbA1c.<br /><br />Findings:<br />- Group A: 1.8% mean HbA1c reduction<br />- Group B: 1.1% mean HbA1c reduction<br />- 68% of Group A vs. 52% of Group B achieved HbA1c \<7%<br />- Group A: 5.2kg mean weight loss<br />- Group B: 3.1kg mean weight loss<br /><br />Secondary endpoints showed improvements in blood pressure and lipid profiles for both groups, with Group A showing slightly better results.<br /><br />Safety: Similar adverse event profiles, with no serious events attributed to either treatment.<br /><br />Clinical Implications: The dual GLP-1/GIP agonist demonstrates superior glycemic control and weight loss compared to standard GLP-1 therapy. These results suggest it could be a significant advancement, particularly for obese diabetics. However, longer-term studies are needed to confirm sustained efficacy and safety, as well as to investigate potential benefits on cardiovascular outcomes. |
  </Accordion>
</AccordionGroup>

***

---

**ðŸ“š [Back to Index](./index.md)** | **ðŸ“„ [Full Version](./documentation.md)** | **ðŸ”— [Original](../llms-full.txt)**
